Evolving Strategies in Platinum-Resistant Ovarian Cancer: Bridging Evidence, Regulation, and Clinical Care Industry Supported Symposium
Activity Overview
The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend the Evolving Strategies in Platinum-Resistant Ovarian Cancer: Bridging Evidence, Regulation, and Clinical Care Industry Supported Symposium being held in-person at the ESGO 2026 Congress in Copenhagen, Denmark on Friday, February 27, 2026 from 13:40 – 14:40 GMT+1.
This symposium will deliver a focused update on emerging strategies for platinum-resistant ovarian cancer, with practical insights on translating evidence into everyday clinical care. Faculty will examine how antibody–drug conjugates, particularly mirvetuximab soravtansine, have redefined treatment for folate receptor-alpha–positive disease, alongside advances in targeted agents, immunotherapy combinations, and other novel approaches. Key trial data, biomarker-driven patient selection, and sequencing strategies will be discussed, with attention to EMA approvals, guideline updates, and toxicity management. A moderated panel will connect these advances to real-world practice, bridging international evidence with regulatory and healthcare system realities.
This educational activity is supported by an independent medical education grant from Corcept Therapeutics, Inc.
Target Audience
The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.
Learning Objectives
Upon completion of the activities in this series, learners will be able to:
- Critically evaluate pivotal data in platinum-resistant ovarian cancer, including efficacy, safety, and quality-of-life outcomes from recent European and global congresses.
- Position novel therapeutic strategies, beyond ADCs, include targeted agents and immunotherapy combinations, within evolving European treatment algorithms.
- Apply progression-free and overall survival data to guide patient selection, sequencing, and shared decision-making in routine care.
- Integrate biomarker-driven strategies, particularly FRα, BRCA, and HRD status, to personalize therapy.
- Navigate regulatory and guideline nuances, implement effective toxicity management, and adapt trial evidence to routine practice.
Agenda
Evolving Strategies in Platinum-Resistant Ovarian Cancer: Bridging Evidence, Regulation, and Clinical Care, an Industry Supported Symposium at the ESGO 2026 Congress
This session is not included in the main event CME/CPD credit.
In Person on Friday, February 27, 2026 from 13:40 – 14:40 GMT+1 in Copenhagen, Denmark
Register Today for the ESGO 2026 Congress
All Faculty
All Faculty